Corona Remedies IPO: Price Band Set ₹1,008-₹1,062; Subscription Opens December 8

Wednesday, December 03, 2025: The initial public offering of Corona Remedies will open on December 8, 2025, at a price range of ₹1008 to ₹1062 a share. The subscription period of three days will end on December 10. 

The objectives of the IPO by the pharmaceutical firm is to raise ₹655.37 crore under an Offer for Sale where promoters and current shareholders will be selling 61.71 lakh shares. As Corona Remedies IPO has no fresh issue attached to it, the company will not get new capital. The anchor allocation would be made on 5th December and the stock would be listed on BSE and NSE on 15th December.

Corona Remedies IPO Pricing and Structure

The floor and cap price are 100.80 and 106.20 times of the face value of 10, respectively at ₹1008.00 to ₹1062.00 per share. The bid lots are 14 shares and higher with the multiples being 14. The problem is pursued in a systematic reservation model in which a maximum of 50% of shares is reserved to qualified institutional buyers, a minimum of 15% to non-institutional investors, and a minimum of 35% of retail investors. 

Moreover, employees have been allocated ₹58.50 million worth of shares. The book-running will be led by JM Financial, IIFL Capital, and Kotak capital whereas registration will be carried out by Bigshare Services.

Corona Remedies Significant Allotment Process and Dates

The important milestones of the IPO should be pointed out to the investors. The subscription will occur between December 8 and 10. On December 11, allotment based on the basis will be finalized. The refund to the unsuccessful applicants will be done on December 12 and on the same day shares will be credited in the demat accounts of successful bidders. The trading is suggested December 15 which will be the debut of the company in the public market.

Corona Remedies Offer to Sale and Shareholder Exit Plan

The whole IPO will be a sale through Offer wherein the existing shareholders, namely Sepia Investments, Anchor Partners and Sage Investment Trust will be able to dilute their interests. These investors will receive the money in the form of the proceeds of the sale. The IPO is not a fund-raising exercise to expand the business or fund operations since no new capital is being raised and the main aim is to exit the current stakeholders.

Company History and Positioning

Corona Remedies is a diversified pharmaceutical corporation that functions in various fields of therapy including women health, cardiovascular care, diabetes, pain management and urology. CRISIL ranks it as the second fastest-growing company among the top 30 companies in the Indian Pharmaceutical Market between June 2022 and June 2025 whose domestic sales have a CAGR of 16.77% compared to the market 9.21. 

The listed peers of the company are Abbott India, the Alkem Laboratories, Eris Lifesciences, Pfizer, Mankind Pharma et cetera which represent a competitive industry with a robust valuation.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations